Will Glenmark’s COVID-19 drug give it a new lease of life or just a short energy boost?

The pharma major has taken a different path from peers, in launching a new drug instead of inking a licensing deal 


Every pharma company worth its salt or API is scrambling for a COVID-19 cure. Since the onset of the pandemic, within a few months, there have been several announcements on clinical trials to treat the virus. With any other illness, such activity would have been paced over years. While most Indian companies chose to ink licensing agreements to manufacture and distribute Gilead’s Remdesivir, Glenmark has taken a different path — of manufacturing a generic of Favipiravir under the brand name FabiFlu.